Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAF<sup>V600E</sup> mutated, microsatellite-stable colon cancer: A case report and literature review. This evidence concerns the gene BRAF and malignant colon neoplasm.